ECSP12012314A - Factor viii conjugado para coagulación de la sangre - Google Patents

Factor viii conjugado para coagulación de la sangre

Info

Publication number
ECSP12012314A
ECSP12012314A ECSP12012314A ECSP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A EC SP12012314 A ECSP12012314 A EC SP12012314A
Authority
EC
Ecuador
Prior art keywords
factor viii
blood coagulation
fviii
conjugated factor
conjugated
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of ECSP12012314A publication Critical patent/ECSP12012314A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ECSP12012314 2010-04-30 2012-11-28 Factor viii conjugado para coagulación de la sangre ECSP12012314A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
ECSP12012314A true ECSP12012314A (es) 2013-05-31

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012314 ECSP12012314A (es) 2010-04-30 2012-11-28 Factor viii conjugado para coagulación de la sangre

Country Status (26)

Country Link
US (1) US20130150302A1 (https=)
EP (1) EP2563402A1 (https=)
JP (1) JP5870088B2 (https=)
KR (1) KR20130055619A (https=)
CN (1) CN102939108A (https=)
AP (1) AP2012006575A0 (https=)
AU (1) AU2011247147B2 (https=)
BR (1) BR112012027590A2 (https=)
CA (1) CA2797058A1 (https=)
CL (1) CL2012003039A1 (https=)
CO (1) CO6660443A2 (https=)
CR (1) CR20120579A (https=)
EA (1) EA201290938A1 (https=)
EC (1) ECSP12012314A (https=)
GB (2) GB201007357D0 (https=)
IL (1) IL222566A (https=)
MX (1) MX2012012683A (https=)
MY (1) MY160922A (https=)
NI (1) NI201200160A (https=)
NZ (1) NZ603939A (https=)
PE (1) PE20130254A1 (https=)
PH (1) PH12012502150A1 (https=)
RU (1) RU2012144555A (https=)
SG (1) SG184906A1 (https=)
WO (1) WO2011135307A1 (https=)
ZA (1) ZA201208989B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
MX2020012103A (es) 2018-05-18 2021-01-29 Zhengzhou Gensciences Inc Proteina de fusion fviii mejorada y uso de la misma.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
DK2280734T3 (da) * 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
AU2009275358C1 (en) * 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
CL2012003039A1 (es) 2014-01-24
MY160922A (en) 2017-03-31
JP5870088B2 (ja) 2016-02-24
HK1173946A1 (en) 2013-05-31
IL222566A0 (en) 2012-12-31
RU2012144555A (ru) 2014-06-10
IL222566A (en) 2017-12-31
ZA201208989B (en) 2014-02-26
GB2492935A8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
GB201220667D0 (en) 2013-01-02
AP2012006575A0 (en) 2012-12-31
SG184906A1 (en) 2012-11-29
PE20130254A1 (es) 2013-03-16
GB201007357D0 (en) 2010-06-16
GB2492935B (en) 2014-04-30
CR20120579A (es) 2013-04-25
BR112012027590A2 (pt) 2016-08-09
PH12012502150A1 (en) 2013-02-04
NZ603939A (en) 2013-08-30
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
CN102939108A (zh) 2013-02-20
GB2492935A (en) 2013-01-16
JP2013525414A (ja) 2013-06-20
GB2492935B8 (en) 2014-10-29
CO6660443A2 (es) 2013-04-30
WO2011135307A1 (en) 2011-11-03
EP2563402A1 (en) 2013-03-06
MX2012012683A (es) 2013-04-03
NI201200160A (es) 2013-04-19
KR20130055619A (ko) 2013-05-28
AU2011247147B2 (en) 2014-09-18
CA2797058A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
ECSP12012314A (es) Factor viii conjugado para coagulación de la sangre
ECSP12012315A (es) FACTOR VIIa CONJUGADO PARA COAGULACIÓN DE LA SANGRE
BR112012017488A2 (pt) "dispositivo"
CY1121560T1 (el) Ανοσογονικη συνθεση
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
CY1118680T1 (el) Φαρμακευτικη συνθεση
BRPI0917920B8 (pt) expansão direcional de dispositivos intraluminais
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
BR112012020790A2 (pt) anticorpo de neutralização da integrina alfavbeta8
EP2830521A4 (en) GLENOID IMPLANT SURGERY USING PATIENT SPECIFIC INSTRUMENTS
GT201300208A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
MX2013003365A (es) Composicion farmaceutica.
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
MX2011011730A (es) Micelas polimericas que contienen sn-38 para el tratamiento de cancer.
BR112012029304A2 (pt) copolíme-ros em bloco de polissiloxano e seu uso em formulações cosmeticas
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης